World's Best Scientists 2026 revealed!
Herbert Hurwitz

Herbert Hurwitz

D-Index & Metrics

Medicine

D-Index
86
Citations
45286
World Ranking
13860
National Ranking
7036

Overview

Herbert Hurwitz is affiliated with Duke University in the United States and has contributed extensively to the field of medicine, with a primary focus on oncology. Their scholarly work spans numerous subfields, including oncology, pulmonary and respiratory medicine, cancer research, pathology and forensic medicine, and hepatology.

Their research topics cover various aspects of cancer treatment and study, especially colorectal and gastric cancers. Key topic areas include colorectal cancer treatments and studies, gastric cancer management and outcomes, cancer treatment and pharmacology, cancer genomics and diagnostics, genetic factors in colorectal cancer, hepatocellular carcinoma treatment and prognosis, and pancreatic and hepatic oncology research.

Frequent publication venues for Herbert Hurwitz include the Journal of Clinical Oncology, UNC Libraries, European Journal of Cancer, Clinical Cancer Research, and Cancers. Their publication record shows a particular concentration in leading oncology journals.

Notable recent papers authored or co-authored by Herbert Hurwitz are:

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook, 2020, Cancer Treatment Reviews
  • Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer, 2020, Journal of Clinical Oncology
  • Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer, 2022, JAMA Network Open
  • Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218, 2020, Clinical Cancer Research
  • Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer, 2020, Clinical Cancer Research

Herbert Hurwitz has collaborated frequently with several researchers including Qian Shi, Aimery de Gramont, Benoist Chibaudel, John Zalcberg, and Leonard B. Saltz, highlighting a network of professional associations within oncology research.

Best Publications

  • BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

    Herbert Hurwitz;Louis Fehrenbacher;William Novotny;Thomas Cartwright

  • Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

    Fairooz Kabbinavar;Herbert I. Hurwitz;Louis Fehrenbacher;Neal J. Meropol

  • Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

    Frank A. Scappaticci;Jamey R. Skillings;Scott N. Holden;Hans Peter Gerber

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Louis Fehrenbacher;John D. Hainsworth;William Heim

  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

    Fairooz F. Kabbinavar;Julie Hambleton;Robert D. Mass;Herbert I. Hurwitz

  • Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

    Howard A. Burris;Herbert I. Hurwitz;E. Claire Dees;Afshin Dowlati

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

    Josep Garcia;Herbert I. Hurwitz;Alan B. Sandler;David Miles

  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

    Frank A. Scappaticci;Louis Fehrenbacher;Thomas Cartwright;John D. Hainsworth

  • Phase I Trial of Pazopanib in Patients with Advanced Cancer

    Herbert I. Hurwitz;Afshin Dowlati;Shermini Saini;Shawna Savage

  • Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

    Adrian M. Jubb;Herbert I. Hurwitz;Wei Bai;Eric B. Holmgren

  • Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

    Fotios Loupakis;Dongyun Yang;Linda Yau;Shibao Feng

  • Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA

    Carlos Micames;Paul S Jowell;Rebekah White;Erik Paulson

  • Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

    Neil L. Spector;Wenle Xia;Howard Burris;Herbert Hurwitz

  • Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study

    John D. Hainsworth;Funda Meric-Bernstam;Charles Swanton;Herbert Hurwitz

  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

    Funda Meric-Bernstam;Herbert Hurwitz;Kanwal Pratap Singh Raghav;Robert R McWilliams

  • Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

    William L. Ince;Adrian M. Jubb;Scott N. Holden;Eric B. Holmgren

  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

    S. N. Holden;S. G. Eckhardt;R. Basser;R. de Boer

  • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

    H. L. Kindler;D. Niedzwiecki;D. Hollis;E. Oraefo

  • The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Jing Yi;William Ince;William F. Novotny

Frequent Co-Authors

Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Michael A. Morse
Michael A. Morse Duke University
Gerard C. Blobe
Gerard C. Blobe Duke University
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Theodore N. Pappas
Theodore N. Pappas Duke University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
John D. Hainsworth
John D. Hainsworth Sarah Cannon Research Institute
Christopher G. Willett
Christopher G. Willett Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering additional career options in medicine beyond the traditional MD route, there are several flexible online degrees available. Many students and professionals are looking to expand their qualifications in fields like management, nursing, and pharmacy—all of which are essential to healthcare.

An important factor to consider when exploring these educational opportunities is cost. Comparing healthcare administration degree cost can help you find programs that match your budget and career goals. If you're interested in leadership or administrative roles, there are a number of affordable mha online programs designed to fit busy schedules.

Nursing professionals can take the next step with the cheapest online dnp programs, making advanced practice and leadership roles accessible without the burden of high tuition. In the field of pharmacology, students can pursue a PharmD from home by researching options for pharmacy school online.

These affordable online programs open new career pathways in healthcare while helping you manage both time and finances effectively.

Best Scientists Citing Herbert Hurwitz

Trending Scientists

Recently Published Articles